Stockscreener 앱 받기
7.60
0.40%
0.03
시장 영업 전:
7.60
전일 마감가:
$7.57
열려 있는:
$7.59
하루 거래량:
176.09K
Relative Volume:
0.58
시가총액:
$509.02M
수익:
$555.06M
순이익/손실:
$-39.48M
주가수익비율:
-12.67
EPS:
-0.6
순현금흐름:
$29.05M
1주 성능:
-0.65%
1개월 성능:
+0.66%
6개월 성능:
+16.39%
1년 성능:
-31.16%
1일 변동 폭
$7.47
$7.64
1주일 범위
$7.33
$7.73
52주 변동 폭
$5.81
$11.89
Bioventus Inc Stock (BVS) Company Profile
명칭
Bioventus Inc
전화
(919) 474-6700
주소
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
BVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
7.60 | 507.01M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
125.40 | 217.86B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.72 | 146.12B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
364.35 | 139.95B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.99 | 130.73B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.78 | 48.73B | 5.88B | 1.34B | 799.60M | 2.3489 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-07 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2022-11-22 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-11-09 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2022-03-15 | 개시 | Craig Hallum | Buy |
| 2021-11-15 | 재개 | Morgan Stanley | Overweight |
| 2021-11-10 | 재개 | JP Morgan | Overweight |
| 2021-07-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-08 | 개시 | Canaccord Genuity | Buy |
| 2021-03-08 | 개시 | Goldman | Buy |
| 2021-03-08 | 개시 | JP Morgan | Overweight |
| 2021-03-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioventus Inc 주식(BVS)의 최신 뉴스
Will Bioventus Inc. stock reach Wall Street targetsTrade Exit Summary & Real-Time Market Sentiment Reports - Newser
Will Bioventus Inc. stock see insider buyingWeekly Stock Report & Short-Term High Return Ideas - Newser
(BVS) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Bioventus: A New Start (NASDAQ:BVS) - Seeking Alpha
How Bioventus Inc. stock performs in weak economy2025 Top Gainers & Reliable Volume Spike Alerts - Newser
Bioventus (NYSE:BVS) Trading Down 3.9%Here's What Happened - MarketBeat
Bioventus, Inc. Reports Strong Q3 Earnings Growth - MSN
Segall Bryant & Hamill LLC Purchases 232,302 Shares of Bioventus Inc. $BVS - MarketBeat
Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly - 富途牛牛
[Form 3] Bioventus Inc. Initial Statement of Beneficial Ownership - Stock Titan
Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Bioventus (Nasdaq: BVS) to present at Piper Sandler 37th Healthcare Conference webcast - Stock Titan
Bioventus (NYSE:BVS) Shares Up 9.9%Time to Buy? - MarketBeat
Bioventus Appoints Ajay Dhankhar as New Director - MSN
Is Bioventus Inc. stock affected by interest rate hikesRisk Management & Weekly Chart Analysis and Guides - newser.com
Why Bioventus Inc. stock appeals to analystsJuly 2025 Decliners & Weekly Market Pulse Updates - newser.com
Is Bioventus Inc. stock attractive for income investorsMarket Trend Review & Risk Adjusted Buy and Sell Alerts - newser.com
Bioventus Inc. stock prediction for this weekDollar Strength & High Conviction Investment Ideas - newser.com
Smart tools for monitoring Bioventus Inc.’s price actionEarnings Beat & Technical Pattern Alert System - newser.com
Can Bioventus Inc. rally from current levelsJuly 2025 Catalysts & Community Trade Idea Sharing Platform - newser.com
Bioventus Inc. (BVS) Stock Forecast 2026, 2030 & 7-Year Price Prediction | Meyka AI - Meyka
Bioventus appoints Ajay Dhankhar to board as Class II director By Investing.com - Investing.com Australia
Bioventus appoints Ajay Dhankhar to board as Class II director - Investing.com
Bioventus Inc. Appoints Ajay Dhankhar to Board of Directors - TradingView
Bioventus Inc. Appoints Ajay Dhankhar to the Board as Class II Director, Effective November 14, 2025 - MarketScreener
[8-K] Bioventus Inc. Reports Material Event | BVS SEC FilingForm 8-K - Stock Titan
Campbell & CO Investment Adviser LLC Makes New Investment in Bioventus Inc. $BVS - MarketBeat
Backtesting results for Bioventus Inc. trading strategiesJuly 2025 Breakouts & Technical Buy Zone Confirmations - newser.com
Will Bioventus Inc. stock deliver long term returnsMarket Growth Report & Safe Capital Growth Trade Ideas - newser.com
Will Bioventus Inc. stock maintain momentum in 2025Treasury Yields & Technical Analysis for Trade Confirmation - newser.com
Developing predictive dashboards with Bioventus Inc. dataQuarterly Portfolio Report & AI Forecast for Swing Trade Picks - newser.com
How strong is Bioventus Inc. stock revenue growthEarnings Risk Report & High Return Stock Watch Alerts - newser.com
Why Bioventus Inc. stock is trending among retail traders2025 Retail Activity & Real-Time Stock Entry Alerts - newser.com
Bioventus Inc (BVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.89%
4.92%
자본화:
|
볼륨(24시간):